Vaxcyte
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-12-01
- Employees
- 254
- Market Cap
- $8.7B
- Website
- http://www.vaxcyte.com
- Introduction
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
- Conditions
- Pneumococcal Vaccines
- Interventions
- Biological: 0.5 mL of the low dose VAX-31Biological: 0.5 mL of the mid dose VAX-31Biological: 0.5 mL of the high dose VAX-31Biological: 0.5 mL dose of PCV20
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Vaxcyte, Inc.
- Target Recruit Count
- 800
- Registration Number
- NCT06720038
- Locations
- 🇺🇸
Orange County Research Institute, Ontario, California, United States
🇺🇸Center for Clinical Trials of San Gabriel, West Covina, California, United States
🇺🇸Children's Hospital of Colorado - Dept. of Infectious Disease, Aurora, Colorado, United States
Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
- Conditions
- Pneumococcal Vaccines
- Interventions
- Biological: 20 valent pneumococcal conjugate vaccine
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Vaxcyte, Inc.
- Target Recruit Count
- 1015
- Registration Number
- NCT06151288
- Locations
- 🇺🇸
Coastal Carolina Research, North Charleston, South Carolina, United States
🇺🇸DM Clinical Research - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸WR-CRCN, Las Vegas, Nevada, United States
Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants
- Conditions
- Pneumococcal Vaccines
- Interventions
- Biological: 0.5 ml dose of 2.2 mcg VAX-24Biological: 0.5 ml dose of 1.1 mcg VAX-24Biological: 0.5 ml dose of PCV20Biological: 0.5 ml dose of 2.2/4.4 mcg VAX-24
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Vaxcyte, Inc.
- Target Recruit Count
- 802
- Registration Number
- NCT05844423
- Locations
- 🇺🇸
UPMC Primary Care Center Oakland, Pittsburgh, Pennsylvania, United States
🇺🇸The Children's Clinic of Jonesboro, P.A., Jonesboro, Arkansas, United States
🇺🇸Madera Family Medical Group, Madera, California, United States
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults
- Conditions
- Pneumococcal Vaccines
- Interventions
- Biological: 24-Valent Pneumococcal Conjugate Vaccine
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Vaxcyte, Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT05297578
- Locations
- 🇺🇸
Accel Research Sites - DeLand Clinical Research Unit, DeLand, Florida, United States
🇺🇸Accellacare of Rocky Mount, Rocky Mount, North Carolina, United States
🇺🇸Healthcare Research Network, Hazelwood, Missouri, United States
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults
- Conditions
- Pneumococcal Vaccines
- Interventions
- Biological: 24 valent pneumococcal conjugate vaccineBiological: 20 valent pneumococcal conjugate vaccine
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Vaxcyte, Inc.
- Target Recruit Count
- 835
- Registration Number
- NCT05266456
- Locations
- 🇺🇸
Meridian Clinical Research, Savannah, Georgia, United States
🇺🇸Benchmark Research, San Angelo, Texas, United States
🇺🇸Johnson County Clin-Trials, Lenexa, Kansas, United States